Cancer Chemotherapy and Pharmacology

, Volume 58, Issue 2, pp 195–202

Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells

Original Article

Abstract

Purpose: Pentoxifylline (PTX), a methyl xanthine derivative is widely used as a haemorheological agent in the treatment of peripheral vascular disease. In the present study, we investigated the in vitro effects of PTX on B16F10 melanoma cell proliferation, adhesion and secretion of Matrix metalloproteinases. Methods: The toxic range of PTX was evaluated using MTT test and colony formation assay. The cell cycle study of PTX treated cells was carried out using flow cytometric analysis. Adhesion assay of pretreated melanoma cells was carried out on extracellular matrix (ECM) substrates. The relative levels and activity of matrix metalloprotienase-9 (MMP-9) and MMP-2 were determined by gelatin zymography and western blotting. Results: Pentoxifylline significantly inhibited the in vitro proliferation of B16F10 cells in a concentration dependent manner and displayed an IC50 of 15.2 mM. Non-cytotoxic concentration of 1–3 mM of PTX for an exposure of 24 h demonstrated significant changes in cell morphology. A significant inhibition in G1-S phase transition was observed on PTX treatment. Pretreated F10 cells showed inhibition in adhesion to ECM components and markedly inhibited the secretion of MMP-9 and MMP-2 gelatinases. Conclusion: The results suggest that PTX even at non-toxic pharmacological concentrations acts as an effective antiproliferative agent with significant antiproteolytic and antiadhesive effects.

Keywords

Pentoxifylline B16F10 melanoma Adhesion Proliferation Matrix metalloproteinases 

References

  1. 1.
    Amirkhosravi A, Warnes G, Biggerstaff J, Malik Z, May K, Francis JL (1997) The effect of pentoxifylline on spontaneous and experimental metastasis of the mouse Neuro2a neuroblastoma. Clin Exp Metastasis 4:453–461CrossRefGoogle Scholar
  2. 2.
    Bennewith KL, Durand RE (2001) Drug-induced alterations in tumor perfusion yield increases in tumor cell radiosensitivity. Br J Cancer 85:1577–1584PubMedCrossRefGoogle Scholar
  3. 3.
    Brinckerhoff CE, Matrician LM (2002) Matrix metalloproteases a tail of frog that became a Prince. Nat Rev Mol Cell Biol 3:204–221CrossRefGoogle Scholar
  4. 4.
    Chun-Lin Ye, Jian-Wen Liu, Dong-Zhi Wei, Yan-Hua Lu, Feng Qian (2004). In vitro anti-tumor activity of 2′, 4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone against six established human cancer cell lines. Pharmacol Res 50(5):505–510PubMedCrossRefGoogle Scholar
  5. 5.
    Demierre MF, Nathanson L (2003) Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 21:158–165PubMedCrossRefGoogle Scholar
  6. 6.
    Ducloux D, Bresson Vautrin C, Chalopin J (2001) Use of pentoxifylline in membranous nephropathy. Lancet 357:1672–1673PubMedCrossRefGoogle Scholar
  7. 7.
    Edward M, Gold JA, Mackie RM (1988) Different susceptibilities of melanoma cell to retinoic acid-induced changes in melanotic expression. Biochem Biophys Res Commun 155:773–778PubMedCrossRefGoogle Scholar
  8. 8.
    Felding HB (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203–213CrossRefGoogle Scholar
  9. 9.
    Fidler IJ (1973) Selection of successive tumor lines for metastasis. Nat (New Biol) 242:148–149Google Scholar
  10. 10.
    Gallagher HC, Bacon CL, Odumeru OA, Gallagher KF, Fitzpatrick T, Regan CM (2004) Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol Teratol 26:73–81PubMedCrossRefGoogle Scholar
  11. 11.
    Gude RP, Binda MM, Boquete AL, Bonfil RD (2001). Inhibition of endothelial cell proliferation and tumor induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol 127:625–630PubMedCrossRefGoogle Scholar
  12. 12.
    Gude RP, Binda MM, Prasas HL, Andres JP, Klein-Santo R, Bonfil D (1996) Studies on mechanisms responsible for inhibition of experimental metastasis of B16F10 murine melanoma by pentoxifyllline. J Biomed Sci 6:133–141CrossRefGoogle Scholar
  13. 13.
    Gude RP, Ingle AD, Rao SGA (1996) Inhibition on lung homing of B16F10 by Pentoxifylline, microfilament depolymerising agent. Cancer Lett 106:171–176PubMedCrossRefGoogle Scholar
  14. 14.
    Kleiner DE, Stetler Stevenson WG (1999) Matrix metalloproteinase and metastasis. Cancer Chemother Pharmacol 43(Suppl):542Google Scholar
  15. 15.
    Lazarczyk M, Grzela T, Niderla J, Lazarczyk MA, Milewski L, Dziunycz P, Skopinski P, Golab J (2004) Differential influence of Pentoxifylline on murine colon adenocarcinoma and melanoma derived metastatic tumor development in lungs. Oncol Rep 11:1121–1125PubMedGoogle Scholar
  16. 16.
    Liotta LA, Rao CN, Wewer UM (1986) Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 55:1037–1057PubMedCrossRefGoogle Scholar
  17. 17.
    LiYe-Xiong S Lin –Quan, Weber-Johnson K (1999). Potentiation of cytotoxicity and radiosensitization of E-2-deoxy-2′-(flouromethylene) cytidine by pentoxifylline in vitro. Int J Cancer 80:155–160CrossRefGoogle Scholar
  18. 18.
    Marnett LJ (1992) Aspirin and role of prostaglandins in colon cancer. Cancer Res 52:5575–5589PubMedGoogle Scholar
  19. 19.
    Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. Embo J 16:2319–2332PubMedCrossRefGoogle Scholar
  20. 20.
    Nicholson C D, Challiss RAJ, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19–27PubMedCrossRefGoogle Scholar
  21. 21.
    Novick WJ, Sullivan G (1990) New Pharmacological Studies with pentoxifylline In: Schimid GM (eds) Biorhology. Schonbein Perogamon Press, USA, 27:449–454Google Scholar
  22. 22.
    Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, Seiki M, Yamashita K, Hayakawa T (1990). Induction and stimulation of 92-kDa gelatinase type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha. Biochem Biophys Res Commun 171:610PubMedCrossRefGoogle Scholar
  23. 23.
    Pavey S, Gabrielli B (2002) Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 62:875–80PubMedGoogle Scholar
  24. 24.
    Peracchia F, Tamburro A, Prontera C, Mariani B, Rotilio D (1997) cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 17:3185–3190PubMedGoogle Scholar
  25. 25.
    Philip S, Bulbule A, Kundu GC (2001) Activation of promatrix metalloproteinase-2 through nuclear factor-κB mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276:44926–44935PubMedCrossRefGoogle Scholar
  26. 26.
    Ries C, Kolb H, Petrides PE (1994) Regulation of 92-kD gelatinase release in HL-60 leukemia cells: Tumor Necrosis Factor-α as an autocrine stimulus for basal and phorbol ester induced secretion. Blood l83:3638–3646Google Scholar
  27. 27.
    Salo T, Liotta LA, Tryggvason K( 1983) Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 258:3058–3063PubMedGoogle Scholar
  28. 28.
    Tatematsu H; Kilkuskie RE; Corrigan AJ; Bodner AJ; Lee K H (1991). Anti-AIDS agents, 3. Inhibitory effects of colchicine derivatives on HIV replication in H9 lymphocyte cells. J Nat Prod 54(2):632–637PubMedCrossRefGoogle Scholar
  29. 29.
    Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E 3rd (1991). Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma. Cancer Chemother Pharmacol 28(1):45–50PubMedCrossRefGoogle Scholar
  30. 30.
    Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B (1991). Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 11(4):1555–1560PubMedGoogle Scholar
  31. 31.
    Toth M, Chvyrkova I, Bernardo M, Barrantes SH, Fridman R (2003) Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 108:386–395CrossRefGoogle Scholar
  32. 32.
    Tryggvason K, Hoyhtya M, Salo T (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 907:191–217PubMedGoogle Scholar
  33. 33.
    Vihinen P and Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of Chemotherapy, Tata Memorial Centre, Advanced Centre for Treatment Research & Education in Cancer (ACTREC)Cancer Research InstituteNavi MumbaiIndia

Personalised recommendations